RenovaCare Appoints President and CEO

RenovaCare Inc., developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, has appointed Alan L. Rubino as president and chief executive officer. Rubino will lead the company through its next stages of clinical and corporate development and financial growth.
 
“RenovaCare’s patent portfolio and technology platform for organ and tissue regeneration is one of the most compelling opportunities I have seen in this sector in my 35 years of industry experience,” stated Rubino. “I look forward to working with the accomplished RenovaCare management team to build value for all our stockholders and bring breakthrough first-in-class regenerative products to market for the benefit of all stakeholders through focused clinical and business development activities in 2020 and beyond.”
 
Rubino is recognized for his many accomplishments in major pharmaceutical and small public specialty companies, and industry board positions, that include therapeutics across a broad range of disease areas, including medical devices to accelerate wound healing and tissue regeneration therapies for burns using innovative stem cell technologies.
 
Recently, Rubino transitioned from Emisphere Technologies Inc. after leading a turnaround over the last seven years and helping to position it among the leading global oral drug delivery firms.
 
The largest part of Rubino’s distinguished career includes a successful 24 years with Hoffmann-La Roche, now Genentech. Rubino led eight large revenue business units (over $1 billion in revenues) and launched the first biologic, Roferon-A (alfa-interferon 2a). Along with being a member of the U.S. Executive and Operating Committees of Roche, Rubino presided over 20 new product launches, ranging from dermatology, organ transplantation, oncology, infectious diseases, CNS, and other therapeutic areas. In addition, he also played a leading executive role in the acquisitions of Syntex Laboratories and Boehringer Mannheim
 
Rubino holds a B.A. in economics from Rutgers University, along with a full minor in biology and chemistry and attended multiple executive education programs at Harvard Business School and the University of Lausanne in Switzerland. Currently, Rubino is also on the board of directors of Vericel Inc., Sanuwave Inc., and Genisphere LLC.
 
Harmel S. Rayat, who resigned as CEO but continues to serve as the company’s chairman of the Board, commented, “Today, as a proud long-term stockholder, I am pleased to welcome Mr.   Alan Rubino, a seasoned and proven industry executive with a history of success and multiple product launches in the healthcare sector. His appointment is among the most exciting inflection points in recent memory.”